Ashok Kumar Gupta

Person

Plainsboro, NJ, US

People

Patents Grantslast 30 patents

Information Patent Grant
Combination of anti-KIR and anti-CTLA-4 antibodies to treat cancer
- Patent number 10,688,180
- Issue date Jun 23, 2020
- Bristol-Myers Squibb Company
- Robert F. Graziano
- A61 - MEDICAL OR VETERINARY SCIENCE HYGIENE
Information Patent Grant
Cancer immunotherapy by disrupting PD-1/PD-L1 signaling
- Patent number 10,604,575
- Issue date Mar 31, 2020
- Bristol-Myers Squibb Company
- John P. Cogswell
- C07 - ORGANIC CHEMISTRY
Information Patent Grant
Cancer immunotherapy by disrupting PD-1/PD-L1 signaling
- Patent number 10,584,170
- Issue date Mar 10, 2020
- Bristol-Myers Squibb Company
- John P. Cogswell
- A61 - MEDICAL OR VETERINARY SCIENCE HYGIENE
Information Patent Grant
Cancer immunotherapy by disrupting PD-1/PD-L1 signaling
- Patent number 10,577,423
- Issue date Mar 3, 2020
- Bristol-Myers Squibb Company
- John P. Cogswell
- C07 - ORGANIC CHEMISTRY
Information Patent Grant
Combination of anti-KIR and anti-CS1 antibodies to treat multiple m...
- Patent number 10,494,433
- Issue date Dec 3, 2019
- Bristol-Myers Squibb Company
- Pascale Andre
- C07 - ORGANIC CHEMISTRY
Information Patent Grant
Cancer immunotherapy by disrupting PD-1/PD-L1 signaling
- Patent number 10,323,092
- Issue date Jun 18, 2019
- Bristol-Myers Squibb Company
- John P. Cogswell
- A61 - MEDICAL OR VETERINARY SCIENCE HYGIENE
Information Patent Grant
Cancer immunotherapy by disrupting PD-1/PD-L1 signaling
- Patent number 10,323,093
- Issue date Jun 18, 2019
- Bristol-Myers Squibb Company
- John P. Cogswell
- A61 - MEDICAL OR VETERINARY SCIENCE HYGIENE
Information Patent Grant
Cancer immunotherapy by disrupting PD-1/PD-L1 signaling
- Patent number 10,316,091
- Issue date Jun 11, 2019
- Bristol-Myers Squibb Company
- John P. Cogswell
- C07 - ORGANIC CHEMISTRY
Information Patent Grant
Cancer immunotherapy by disrupting PD-1/PD-L1 signaling
- Patent number 10,316,090
- Issue date Jun 11, 2019
- Bristol-Myers Squibb Company
- John P. Cogswell
- C07 - ORGANIC CHEMISTRY
Information Patent Grant
Cancer immunotherapy by disrupting PD-1/PD-L1 signaling
- Patent number 10,308,714
- Issue date Jun 4, 2019
- Bristol-Myers Squibb Company
- John P. Cogswell
- G01 - MEASURING TESTING
Information Patent Grant
Cancer immunotherapy by disrupting PD-1/PD-L1 signaling
- Patent number 10,266,596
- Issue date Apr 23, 2019
- Bristol-Myers Squibb Company
- John P. Cogswell
- C07 - ORGANIC CHEMISTRY
Information Patent Grant
Cancer immunotherapy by disrupting PD-1/PD-L1 signaling
- Patent number 10,266,594
- Issue date Apr 23, 2019
- Bristol-Myers Squibb Company
- John P. Cogswell
- C07 - ORGANIC CHEMISTRY
Information Patent Grant
Cancer immunotherapy by disrupting PD-1/PD-L1 signaling
- Patent number 10,266,595
- Issue date Apr 23, 2019
- Bristol-Myers Squibb Company
- John P. Cogswell
- C07 - ORGANIC CHEMISTRY
Information Patent Grant
Cancer immunotherapy by disrupting PD-1/PD-L1 signaling
- Patent number 10,138,299
- Issue date Nov 27, 2018
- Bristol-Myers Squibb Company
- John P. Cogswell
- C07 - ORGANIC CHEMISTRY
Information Patent Grant
Cancer immunotherapy by disrupting PD-1/PD-L1 signaling
- Patent number 10,072,082
- Issue date Sep 11, 2018
- Bristol-Myers Squibb Company
- John P. Cogswell
- C07 - ORGANIC CHEMISTRY
Information Patent Grant
Cancer immunotherapy by disrupting PD-1/PD-L1 signaling
- Patent number 9,856,320
- Issue date Jan 2, 2018
- Bristol-Myers Squibb Company
- John P. Cogswell
- A61 - MEDICAL OR VETERINARY SCIENCE HYGIENE
Information Patent Grant
Combination of anti-KIR and anti-CTLA-4 antibodies to treat cancer
- Patent number 9,789,182
- Issue date Oct 17, 2017
- Bristol-Myers Squibb Company
- Robert F. Graziano
- A61 - MEDICAL OR VETERINARY SCIENCE HYGIENE
Information Patent Grant
Antibodies that bind PD-L1 and uses thereof
- Patent number 9,212,224
- Issue date Dec 15, 2015
- Bristol-Myers Squibb Company
- John Cogswell
- A61 - MEDICAL OR VETERINARY SCIENCE HYGIENE

Patents Applicationslast 30 patents

Information Patent Application
CANCER IMMUNOTHERAPY BY DISRUPTING PD-1/PD-L1 SIGNALING
- Publication number 20240417471
- Publication date Dec 19, 2024
- Bristol-Myers Squibb Company
- John P. COGSWELL
- A61 - MEDICAL OR VETERINARY SCIENCE HYGIENE
Information Patent Application
CANCER IMMUNOTHERAPY BY DISRUPTING PD-1/PD-L1 SIGNALING
- Publication number 20240034793
- Publication date Feb 1, 2024
- Bristol-Myers Squibb Company
- John P. COGSWELL
- G01 - MEASURING TESTING
Information Patent Application
CANCER IMMUNOTHERAPY BY DISRUPTING PD-1/PD-L1 SIGNALING
- Publication number 20240002512
- Publication date Jan 4, 2024
- Bristol-Myers Squibb Company
- John P. COGSWELL
- A61 - MEDICAL OR VETERINARY SCIENCE HYGIENE
Information Patent Application
ANTI-PD-L1 ANTIBODY TREATMENT OF BLADDER CANCER
- Publication number 20220332828
- Publication date Oct 20, 2022
- Medimmune, LLC
- JOHN KURLAND
- C07 - ORGANIC CHEMISTRY
Information Patent Application
TREATMENT OF CANCER
- Publication number 20210253694
- Publication date Aug 19, 2021
- MEDIMMUNE LIMITED
- SHAAD ESSA ABDULLAH
- A61 - MEDICAL OR VETERINARY SCIENCE HYGIENE
Information Patent Application
CANCER IMMUNOTHERAPY BY DISRUPTING PD-1/PD-L1 SIGNALING
- Publication number 20200308282
- Publication date Oct 1, 2020
- Bristol-Myers Squibb Company
- John P. COGSWELL
- A61 - MEDICAL OR VETERINARY SCIENCE HYGIENE
Information Patent Application
ANTI-PD-L1 ANTIBODY TREATMENT OF BLADDER CANCER
- Publication number 20190359715
- Publication date Nov 28, 2019
- Medimmune, LLC
- JOHN KURLAND
- A61 - MEDICAL OR VETERINARY SCIENCE HYGIENE
Information Patent Application
CANCER IMMUNOTHERAPY BY DISRUPTING PD-1/PD-L1 SIGNALING
- Publication number 20190153099
- Publication date May 23, 2019
- Bristol-Myers Squibb Company
- John P. COGSWELL
- C07 - ORGANIC CHEMISTRY
Information Patent Application
CANCER IMMUNOTHERAPY BY DISRUPTING PD-1/PD-L1 SIGNALING
- Publication number 20190135920
- Publication date May 9, 2019
- Bristol-Myers Squibb Company
- John P. COGSWELL
- A61 - MEDICAL OR VETERINARY SCIENCE HYGIENE
Information Patent Application
CANCER IMMUNOTHERAPY BY DISRUPTING PD-1/PD-L1 SIGNALING
- Publication number 20190112377
- Publication date Apr 18, 2019
- Bristol-Myers Squibb Company
- John P. COGSWELL
- A61 - MEDICAL OR VETERINARY SCIENCE HYGIENE
Information Patent Application
CANCER IMMUNOTHERAPY BY DISRUPTING PD-1/PD-L1 SIGNALING
- Publication number 20190112376
- Publication date Apr 18, 2019
- Bristol-Myers Squibb Company
- John P. COGSWELL
- A61 - MEDICAL OR VETERINARY SCIENCE HYGIENE
Information Patent Application
CANCER IMMUNOTHERAPY BY DISRUPTING PD-1/PD-L1 SIGNALING
- Publication number 20190100589
- Publication date Apr 4, 2019
- Bristol-Myers Squibb Company
- John P. COGSWELL
- A61 - MEDICAL OR VETERINARY SCIENCE HYGIENE
Information Patent Application
CANCER IMMUNOTHERAPY BY DISRUPTING PD-1/PD-L1 SIGNALING
- Publication number 20190100590
- Publication date Apr 4, 2019
- Bristol-Myers Squibb Company
- John P. COGSWELL
- A61 - MEDICAL OR VETERINARY SCIENCE HYGIENE
Information Patent Application
CANCER IMMUNOTHERAPY BY DISRUPTING PD-1/PD-L1 SIGNALING
- Publication number 20190092863
- Publication date Mar 28, 2019
- Bristol-Myers Squibb Company
- John P. Cogswell
- C07 - ORGANIC CHEMISTRY
Information Patent Application
CANCER IMMUNOTHERAPY BY DISRUPTING PD-1/PD-L1 SIGNALING
- Publication number 20180319887
- Publication date Nov 8, 2018
- Bristol-Myers Squibb Company
- John P. COGSWELL
- C07 - ORGANIC CHEMISTRY
Information Patent Application
CANCER IMMUNOTHERAPY BY DISRUPTING PD-1/PD-L1 SIGNALING
- Publication number 20180312590
- Publication date Nov 1, 2018
- Bristol-Myers Squibb Company
- John P. COGSWELL
- A61 - MEDICAL OR VETERINARY SCIENCE HYGIENE
Information Patent Application
CANCER IMMUNOTHERAPY BY DISRUPTING PD-1/PD-L1 SIGNALING
- Publication number 20180282413
- Publication date Oct 4, 2018
- Bristol-Myers Squibb Company
- John P. COGSWELL
- A61 - MEDICAL OR VETERINARY SCIENCE HYGIENE
Information Patent Application
CANCER IMMUNOTHERAPY BY DISRUPTING PD-1/PD-L1 SIGNALING
- Publication number 20180282414
- Publication date Oct 4, 2018
- Bristol-Myers Squibb Company
- John P. COGSWELL
- A61 - MEDICAL OR VETERINARY SCIENCE HYGIENE
Information Patent Application
CANCER IMMUNOTHERAPY BY DISRUPTING PD-1/PD-L1 SIGNALING
- Publication number 20180273624
- Publication date Sep 27, 2018
- Bristol-Myers Squibb Company
- John P. COGSWELL
- C07 - ORGANIC CHEMISTRY
Information Patent Application
COMBINATION OF ANTI-KIR AND ANTI-CTLA-4 ANTIBODIES TO TREAT CANCER
- Publication number 20180117147
- Publication date May 3, 2018
- Bristol-Myers Squibb Company
- Robert F. GRAZIANO
- A61 - MEDICAL OR VETERINARY SCIENCE HYGIENE
Information Patent Application
COMBINATION OF ANTI-KIR ANTIBODIES AND ANTI-PD-1 ANTIBODIES TO TREA...
- Publication number 20180099045
- Publication date Apr 12, 2018
- Bristol-Myers Squibb Company
- Robert F. Graziano
- A61 - MEDICAL OR VETERINARY SCIENCE HYGIENE
Information Patent Application
COMBINATION OF ANTI-KIR AND ANTI-CS1 ANTIBODIES TO TREAT MULTIPLE M...
- Publication number 20160257750
- Publication date Sep 8, 2016
- Bristol-Myers Squibb Company
- Pascale ANDRE
- A61 - MEDICAL OR VETERINARY SCIENCE HYGIENE
Information Patent Application
CANCER IMMUNOTHERAPY BY DISRUPTING PD-1/PD-L1 SIGNALING
- Publication number 20160090417
- Publication date Mar 31, 2016
- Bristol-Myers Squibb Company
- JOHN P. COGSWELL
- G01 - MEASURING TESTING
Information Patent Application
COMBINATION OF ANTI-KIR ANTIBODIES AND ANTI-PD-1 ANTIBODIES TO TREA...
- Publication number 20150290316
- Publication date Oct 15, 2015
- Bristol-Myers Squibb Company
- Robert F. Graziano
- A61 - MEDICAL OR VETERINARY SCIENCE HYGIENE
Information Patent Application
COMBINATION OF ANTI-KIR AND ANTI-CTLA-4 ANTIBODIES TO TREAT CANCER
- Publication number 20150283234
- Publication date Oct 8, 2015
- BRISTOL-MYERS SQUIBB COMPANY
- Robert F. Graziano
- A61 - MEDICAL OR VETERINARY SCIENCE HYGIENE
Information Patent Application
CANCER IMMUNOTHERAPY BY DISRUPTING PD-1/PD-L1 SIGNALING
- Publication number 20150125463
- Publication date May 7, 2015
- Bristol-Myers Squibb Company
- John P. Cogswell
- G01 - MEASURING TESTING
Information Patent Application
CANCER IMMUNOTHERAPY BY DISRUPTING PD-1/PD-L1 SIGNALING
- Publication number 20130309250
- Publication date Nov 21, 2013
- John Cogswell
- G01 - MEASURING TESTING
Information Patent Application
COMBINATION OF ANTI-CTLA4 ANTIBODY WITH BRAF INHIBITORS FOR THE SYN...
- Publication number 20130156768
- Publication date Jun 20, 2013
- Bristol-Myers Squibb Company
- Maria Jure-Kunkel
- A61 - MEDICAL OR VETERINARY SCIENCE HYGIENE

Ashok Kumar Gupta

Person

Patents Grantslast 30 patents

Combination of anti-KIR and anti-CTLA-4 antibodies to treat cancer

Cancer immunotherapy by disrupting PD-1/PD-L1 signaling

Cancer immunotherapy by disrupting PD-1/PD-L1 signaling

Cancer immunotherapy by disrupting PD-1/PD-L1 signaling

Combination of anti-KIR and anti-CS1 antibodies to treat multiple m...

Cancer immunotherapy by disrupting PD-1/PD-L1 signaling

Cancer immunotherapy by disrupting PD-1/PD-L1 signaling

Cancer immunotherapy by disrupting PD-1/PD-L1 signaling

Cancer immunotherapy by disrupting PD-1/PD-L1 signaling

Cancer immunotherapy by disrupting PD-1/PD-L1 signaling

Cancer immunotherapy by disrupting PD-1/PD-L1 signaling

Cancer immunotherapy by disrupting PD-1/PD-L1 signaling

Cancer immunotherapy by disrupting PD-1/PD-L1 signaling

Cancer immunotherapy by disrupting PD-1/PD-L1 signaling

Cancer immunotherapy by disrupting PD-1/PD-L1 signaling

Cancer immunotherapy by disrupting PD-1/PD-L1 signaling

Combination of anti-KIR and anti-CTLA-4 antibodies to treat cancer

Antibodies that bind PD-L1 and uses thereof

Patents Applicationslast 30 patents

CANCER IMMUNOTHERAPY BY DISRUPTING PD-1/PD-L1 SIGNALING

CANCER IMMUNOTHERAPY BY DISRUPTING PD-1/PD-L1 SIGNALING

CANCER IMMUNOTHERAPY BY DISRUPTING PD-1/PD-L1 SIGNALING

ANTI-PD-L1 ANTIBODY TREATMENT OF BLADDER CANCER

TREATMENT OF CANCER

CANCER IMMUNOTHERAPY BY DISRUPTING PD-1/PD-L1 SIGNALING

ANTI-PD-L1 ANTIBODY TREATMENT OF BLADDER CANCER

CANCER IMMUNOTHERAPY BY DISRUPTING PD-1/PD-L1 SIGNALING

CANCER IMMUNOTHERAPY BY DISRUPTING PD-1/PD-L1 SIGNALING

CANCER IMMUNOTHERAPY BY DISRUPTING PD-1/PD-L1 SIGNALING

CANCER IMMUNOTHERAPY BY DISRUPTING PD-1/PD-L1 SIGNALING

CANCER IMMUNOTHERAPY BY DISRUPTING PD-1/PD-L1 SIGNALING

CANCER IMMUNOTHERAPY BY DISRUPTING PD-1/PD-L1 SIGNALING

CANCER IMMUNOTHERAPY BY DISRUPTING PD-1/PD-L1 SIGNALING

CANCER IMMUNOTHERAPY BY DISRUPTING PD-1/PD-L1 SIGNALING

CANCER IMMUNOTHERAPY BY DISRUPTING PD-1/PD-L1 SIGNALING

CANCER IMMUNOTHERAPY BY DISRUPTING PD-1/PD-L1 SIGNALING

CANCER IMMUNOTHERAPY BY DISRUPTING PD-1/PD-L1 SIGNALING

CANCER IMMUNOTHERAPY BY DISRUPTING PD-1/PD-L1 SIGNALING

COMBINATION OF ANTI-KIR AND ANTI-CTLA-4 ANTIBODIES TO TREAT CANCER

COMBINATION OF ANTI-KIR ANTIBODIES AND ANTI-PD-1 ANTIBODIES TO TREA...

COMBINATION OF ANTI-KIR AND ANTI-CS1 ANTIBODIES TO TREAT MULTIPLE M...

CANCER IMMUNOTHERAPY BY DISRUPTING PD-1/PD-L1 SIGNALING

COMBINATION OF ANTI-KIR ANTIBODIES AND ANTI-PD-1 ANTIBODIES TO TREA...

COMBINATION OF ANTI-KIR AND ANTI-CTLA-4 ANTIBODIES TO TREAT CANCER

CANCER IMMUNOTHERAPY BY DISRUPTING PD-1/PD-L1 SIGNALING

CANCER IMMUNOTHERAPY BY DISRUPTING PD-1/PD-L1 SIGNALING

COMBINATION OF ANTI-CTLA4 ANTIBODY WITH BRAF INHIBITORS FOR THE SYN...